Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
A single point mutation of the factor V (FV) gene, leading to the substitution Arg506Gln in the FV molecule (FV-Leiden) and hence resistance to its breakdown by activated protein C (APC), is the most prevalent risk factor for venous thrombosis in the Caucasians. A ratio determined by activated partial thromboplastin time (APTT) of test plasma in the presence or absence of exogenous APC (the APC ratio), is the method widely used to screen individuals with this risk factor for thrombosis. Because of functional defects of vitamin K-dependent clotting factors in patients on oral anticoagulant therapy, this method cannot be applied to those patients without modification. One modification is to mix test plasma (1:5 or 1:10) with FV-deficient plasma so that 80-90% of functioning vitamin K-dependent factors are supplied by the FV-deficient plasma. Even with 10-20% of FV in the mixture, APC-resistance still can be demonstrated. In this report, we present our results of the modified APC-sensitivity assay using FV-deficient plasma from different commercial sources. APC ratios determined by the original method in which test plasma is not mixed with FV-deficient plasma can be significantly different from those determined by the modified method in which test plasma is diluted 1:5 with FV-deficient plasma. This difference between methods was observed not only in normal individuals, but also in FV-Leiden positive individuals, and in patients on warfarin therapy. Further, APC ratios varied significantly depending on the commercial source of the FV-deficient plasma. The modified method is apparently suitable to identify APC-resistance in patients on warfarin therapy, as well as in individuals not receiving anticoagulant treatment. However, one must be aware that APC-resistance ratios obtained with the modified method are likely to be different from those established with the original method, and the source of FV-deficient plasma can be a factor influencing the ratios in the former cases.
Ts'ao
C
C
Department of Pathology, Northwestern Memorial Hospital, Chicago, Illinois 60611, USA.
Neofotistos
D
D
Oropeza
M
M
Vahabinejad
S
S
Finn
W G
WG
D000925:Anticoagulants / Q000627:therapeutic use; D001681:Biological Assay / Q000379:methods*; D004351:Drug Resistance; D005165:Factor V / Q000235:genetics / Q000378:metabolism; D005166:Factor V Deficiency / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D017354:Point Mutation; D011486:Protein C / Q000032:analysis / Q000378:metabolism*; D012015:Reference Standards; D012680:Sensitivity and Specificity; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D011486:Protein C; D014859:Warfarin; D005165:Factor V